Latest Shareholder Meeting News

Cyprium Metals has raised A$41 million through an oversubscribed equity placement and entitlement offer to accelerate exploration and production growth at its flagship Nifty Copper Complex and regional projects.

Global Uranium and Enrichment Limited has finalised the share and option scheme considerations for its acquisition by Snow Lake Resources, with directors backing the deal ahead of the upcoming shareholder vote.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

Sunstone Metals is seeking shareholder approval for a 30-for-1 share consolidation aimed at simplifying its capital structure and enhancing investor appeal. The move follows a recent placement that left the company with over 7 billion securities on issue.

Energy Fuels Inc. has announced a binding agreement to acquire Australian Strategic Materials Ltd (ASM) in a deal valuing ASM at approximately A$447 million, offering shareholders a 121% premium. The acquisition aims to establish a vertically integrated Western rare earths supply chain, aligning with critical minerals strategies between the US and Australia.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Askari Metals has responded to an ASX query regarding an inadvertent breach of Listing Rule 10.11 after issuing securities to a related party without prior shareholder approval during a recent rights issue. The company outlines the circumstances and its planned remedial actions.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

Apiam Animal Health has secured Foreign Investment Review Board approval for its acquisition by Adamantem Capital, paving the way for a crucial shareholder vote in February.

Augustus Minerals has addressed ASX concerns over its recent appointment and election of a new director, clarifying compliance with listing rules despite timing challenges.

I Synergy Group Limited has announced a planned 5-for-1 consolidation of its ordinary shares and options, pending shareholder approval. The move aims to reduce the number of securities on issue, with trading of consolidated shares set to begin in early February.

AVA Risk Group has locked in a strategic investment of up to A$12.6 million from US-based Hale Capital, aiming to boost its footprint in the lucrative US critical infrastructure market. The deal includes convertible notes and warrants priced at an 81% premium, alongside a new board appointment.